However, while treatment with SLAMF7 antibody (162) and secondary crosslinker can induce varying levels of tyrosine phosphorylation of the receptor in different myeloma cell lines, SHIP-1 was only minimally tyrosine phosphorylated, if at all (67). This evidence concerns the gene INPP5D and plasma cell myeloma.